4/A: TECX CEO Corrects Stock Purchase Filing

Tectonic Therapeutic CEO Alise Reicin amended a Form 4 to clarify that a recent 2,500 share purchase was made indirectly through a family trust, not directly.

Summary

• An amendment (Form 4/A) was filed to correct a previously submitted Form 4 dated February 12, 2026.
• The reporting person is Alise Reicin, who serves as a Director and Chief Executive Officer of Tectonic Therapeutic, Inc. (TECX).
• On February 11, 2026, 2,500 shares of Common Stock were purchased.
• The shares were acquired at a weighted average price of $21.1, with individual transaction prices ranging from $21.02 to $21.15.
• The correction clarifies that the shares were purchased indirectly by the Reicin-Boiarsky Family Trust, not directly by Alise Reicin.
• Following the reported transaction, 127,030 shares are beneficially owned indirectly by the Trust, and 235,047 shares are directly owned.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal due to the insider purchase, despite the administrative correction, as it reflects management's investment in the company.

Positives

• CEO Alise Reicin, a Director and Chief Executive Officer, increased her beneficial ownership in the company by purchasing 2,500 shares.
• The purchase was made at a weighted average price of $21.1 per share, indicating management's confidence at this price point.

Future Outlook

No specific forward-looking statements or guidance are provided in this amendment.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that insider purchases, even when corrected for ownership structure, often signal management's belief in the company's future prospects, a common indicator watched by investors in the biotech/pharma sector.

Related Party Transactions

• The purchase of 2,500 shares was made by the Reicin-Boiarsky Family Trust, where the Reporting Person's spouse is a co-trustee, indicating a related party transaction.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal of management confidence in the company's future.

Key Dates

Recommendation

The filing primarily serves as an administrative correction to an insider transaction. While the insider purchase itself is a minor positive signal, the amendment does not introduce new material information that would warrant a change in investment strategy. The transaction size is not substantial enough to drive a strong buy or sell recommendation based solely on this filing.

Keywords

Tectonic Therapeutic, TECX, insider trading, Form 4, stock purchase, CEO, beneficial ownership, trust